Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
NRX Pharmaceuticals ( (NRXP) ) has shared an announcement.
On January 12, 2026, NRx Pharmaceuticals disclosed it had received a Nasdaq notice of non-compliance for failing to hold an annual shareholder meeting within 12 months of its fiscal year-end, triggering a requirement to submit a remediation plan within 45 days and placing the company on Nasdaq’s public list of non-compliant issuers, though its NRXP shares continue to trade without immediate impact. In response, the board set March 23, 2026 as the date for the delayed 2025 virtual annual meeting and February 12, 2026 as the record date, and outlined an accelerated January 26, 2026 deadline and procedural requirements for shareholder proposals and director nominations, a step that aims to restore listing compliance while clarifying the timetable and rules for investor participation in corporate governance.
The most recent analyst rating on (NRXP) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on NRX Pharmaceuticals stock, see the NRXP Stock Forecast page.
Spark’s Take on NRXP Stock
According to Spark, TipRanks’ AI Analyst, NRXP is a Neutral.
Overall score reflects weak current financial performance (large losses, negative free cash flow, and negative equity) partially offset by a more optimistic earnings outlook (initial revenue traction, clinic expansion plans, and stated funding through 2026). Technicals are mixed with only modest short-term improvement, and valuation is pressured by negative earnings and no dividend support.
To see Spark’s full report on NRXP stock, click here.
More about NRX Pharmaceuticals
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for central nervous system disorders, focusing on suicidal depression, chronic pain and PTSD. Its lead candidates include NRX-100, a preservative-free intravenous ketamine that has received Fast Track Designation for treating suicidal ideation in depression including bipolar depression, and NRX-101, an oral D-cycloserine/lurasidone combination that has been granted Breakthrough Therapy Designation for suicidal bipolar depression; the company has also filed an Abbreviated New Drug Application and initiated a New Drug Application for NRX-100 in this indication.
Average Trading Volume: 873,963
Technical Sentiment Signal: Sell
Current Market Cap: $63.65M
See more data about NRXP stock on TipRanks’ Stock Analysis page.